Solu Therapeutics

Solu Therapeutics is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, pioneering a novel class of antibody therapeutics that unlock cell-surface targets by combining small molecules with effector antibodies through proprietary linker technology. Its two platform technologies are CyTAC (Cytotoxicity Targeting Chimera), which links cell-surface targets to antibodies that kill pathogenic cells, and TicTAC (Therapeutic Index Control Targeting Chimera), which gives long-acting small-molecule agonists and antagonists antibody-like pharmacokinetics. Its lead program, STX-0712, is a CyTAC targeting the GPCR CCR2 in Phase 1 trials for chronic myelomonocytic leukemia, with additional oncology and immunology programs advancing. Solu is a portfolio company of the venture firm DCVC. The company operates as a drug-discovery and clinical-development organization and publishes no public developer API, developer portal, or programmatic surface.

Solu Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Therapeutics, and Oncology.

🌐 Visit website 📡 Source on GitHub
11.0/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechnologyPharmaceuticalsTherapeuticsOncologyImmunologyAntibodiesDrug DiscoveryClinical Stage

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 11.0/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.0 / 20
Commercial Clarity 4.2 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/solu-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Solu Therapeutics Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy
 TermsOfService
TermsOfService

Company 1

The organization behind the API

Website
Website

Source (apis.yml)

apis.yml Raw ↑ 
aid: solu-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/solu-therapeutics.png
name: Solu Therapeutics
description: Solu Therapeutics is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, pioneering
  a novel class of antibody therapeutics that unlock cell-surface targets by combining small molecules with effector antibodies
  through proprietary linker technology. Its two platform technologies are CyTAC (Cytotoxicity Targeting Chimera), which links
  cell-surface targets to antibodies that kill pathogenic cells, and TicTAC (Therapeutic Index Control Targeting Chimera),
  which gives long-acting small-molecule agonists and antagonists antibody-like pharmacokinetics. Its lead program, STX-0712,
  is a CyTAC targeting the GPCR CCR2 in Phase 1 trials for chronic myelomonocytic leukemia, with additional oncology and immunology
  programs advancing. Solu is a portfolio company of the venture firm DCVC. The company operates as a drug-discovery and clinical-development
  organization and publishes no public developer API, developer portal, or programmatic surface.
url: https://raw.githubusercontent.com/api-evangelist/solu-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- dcvc
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Therapeutics
- Oncology
- Immunology
- Antibodies
- Drug Discovery
- Clinical Stage
apis: []
common:
- type: DomainSecurity
  url: security/solu-therapeutics-domain-security.yml
- type: Website
  url: https://solutherapeutics.com
- type: PrivacyPolicy
  url: https://cdn.prod.website-files.com/669551ccc7908830b842dc2b/66a95195f579f49a0115e1db_Solu%20terms%20of%20use%20%26%20privacy%20policy.pdf
- type: TermsOfService
  url: https://cdn.prod.website-files.com/669551ccc7908830b842dc2b/66a95195f579f49a0115e1db_Solu%20terms%20of%20use%20%26%20privacy%20policy.pdf
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 1
  pass: local-v1